‘Vyndamax,’ a new drug for transthyretin amyloid cardiomyopathy (ATTR-CM), is again attempting reimbursement listing in Korea.

According to industry sources, Pfizer Korea had recently submitted an application for the insurance reimbursement of Vyndamax, its new drug for transthyretin amyloid cardiomyopathy (ATTR-CM).

Vyndamax failed to receive the essential drug designation in its first reimbursement attempt in early 2021. The company then conducted a pharmacoeconomic evaluation in the first half of the same year and made its second attempt through the risk-sharing agreement (RSA) track, but to no avail.

In April 2022, the drug again failed to pass the MFDS’s reim